Skip to main content
OpenTrials
Completed

NCT Number: NCT01119612

Prenatal Iron Supplements: Safety and Efficacy in Tanzania

The purpose of this study is to determine safety and efficacy of prenatal iron supplementation in an area of high malaria burden among women who are not anemic or iron deficient.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Muhimbili University of Health And Allied Sciences

Dar es Salaam, PO BOX 65001, Tanzania

About this study

Iron deficiency anemia and malaria are urgent public health problems in sub-Saharan Africa, including Tanzania. There is a paucity of good quality randomized trials assessing the safety and efficacy of iron supplementation in pregnancy, and its effects on perinatal health outcomes. Prenatal iron supplementation is recommended based on its demonstrated benefit in preventing and treating maternal anemia. There is limited data on the efficacy of iron supplementation on pregnancy outcomes, including birth weight. There are also concerns regarding the use of iron supplementation, particularly among non-anemic women. In particular, there is a lack of research on the safety and efficacy of prenatal iron supplementation in developing regions, characterized by extensive burden of iron deficiency, malaria, and other endemic infectious diseases. Evidence from randomized controlled trials is urgently needed to examine the safety and efficacy of iron supplements among pregnant women in malaria endemic regions, particularly among women who are not anemic.

NOTE: The time frames listed for the maternal malaria and hemoglobin outcomes were updated on 4/22/15. This record initially indicated that maternal malaria anemia and hemoglobin would be measured at several specific time points throughout the study. Instead, maternal malaria was measured throughout pregnancy and hemoglobin was measured only at delivery. Due to an oversight, we did not update this record when this protocol change took effect at the start of the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • at or before 27 weeks of gestation
  • primigravida or secundigravidae
  • not anemic (defined as Hb<8.5 g/dL)
  • not iron deficient (defined as serum ferritin <12 μg/L)
  • HIV-uninfected
  • intend to stay in Dar es Salaam until delivery and for at least six weeks thereafter.

Exclusion criteria

  • After 27 weeks gestation
  • not primigravida or secundigravidae
  • anemic
  • iron deficient
  • HIV-infected
  • High iron stores at baseline (i.e., serum ferritin >200 μg/L)
  • do not intend to stay in Dar es Salaam until delivery and for at least six weeks thereafter.

Treatment and study plan

Iron

Dietary Supplement

Daily oral dose of 60 mg from enrollment until delivery

Placebo

Other

Daily oral dose from enrollment until delivery

Primary outcomes

  1. Incidence of placental malaria

    Time frame: Delivery

    Placental infection status will be categorized as infected if there are asexual parasites in the placenta blood; not infected if the placental blood smear is negative; or status unknown if no placental smear is available.

  2. Placental malaria parasite density

    Time frame: Delivery

    Placental malaria parasite density will be defined as number of parasites per μL of blood or 200 white blood cells; the latter will be converted to a count per μL of blood assuming a count of 8000 WBC/μL.

  3. Infant birth weight

    Time frame: Delivery

    Continuous measurement

  4. Maternal hemoglobin

    Time frame: Delivery

    Continuous measurement

Secondary outcomes

  1. Low birth weight

    Time frame: Delivery

    Low birth weight will be defined as birth weight less than 2500 grams.

  2. Maternal malaria infection

    Time frame: During pregnancy

    Maternal malaria will be defined as fever within the last 72 hours with any parasitemia on a peripheral blood smear.

  3. Maternal anemia

    Time frame: Delivery

    Anemia will be defined as hemoglobin less than 11 g/dl. Severe anemia will be defined as less than 8.5 g/dl.

Sponsors and collaborators

Lead sponsor

Harvard School of Public Health (HSPH)

Other

Collaborators

  • Muhimbili University of Health and Allied Sciences

Registry information

Acronym: MAL1

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
May 7, 2010
Registry last updated
Apr 24, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.